Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL517469 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1325100 | 0.95 | TDP1 (0.55) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL20541913 | 0.94 | TDP1 (0.58) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL20541546 | 0.94 | TDP1 (0.58) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL20541445 | 0.94 | TDP1 (0.58) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1579652 | 0.94 | TDP1 (0.58) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL20541389 | 0.94 | TDP1 (0.58) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL6664857 | 0.90 | CASP3 (0.51) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14764997 | 0.83 | TDP1 (0.50) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| Bromide SCHEMBL20541573 | 0.79 | RAB9A (0.56) | RAB9ACYP1A2CYP2D6CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181039-A | Synthetic method of 4, 4-diphenyl-3-buten-1-ol | 凯美克(上海)医药科技有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| EP-4003989-B1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | SERVIER LAB (FR) | 2023-12-27 | — | — | EP | disclosed |
| US-20220363677-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | VERNALIS (R&D) LTD (GB) | 2022-11-17 | — | — | US | disclosed |
| EP-4003989-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| CN-114181039-A | Synthetic method of 4, 4-diphenyl-3-buten-1-ol | 凯美克(上海)医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114181039-A | Synthetic method of 4, 4-diphenyl-3-buten-1-ol | 凯美克(上海)医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | CHRM2 3620/4885TDP1 2743/4885L3MBTL1 1905/4885 |
| US-20220363677-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | BAK1, BCL2, BCL2A1 | CHRM2 3419/4885TDP1 2719/4885L3MBTL1 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.